
AbbVie (ABBV) Stock Forecast & Price Target
AbbVie (ABBV) Analyst Ratings
Bulls say
AbbVie is a global biopharmaceutical company that specializes in discovering, developing, and commercializing advanced therapies in areas such as immunology, oncology, neuroscience, and aesthetics. The company's strong exposure to these key therapeutic areas, along with its recent acquisitions of Allergan, Cerevel, and ImmunoGen, have contributed to a diverse and robust portfolio of products and drugs. Additionally, AbbVie has shown a commitment to sustainability through its governance and focus on patient access, while also mitigating risks in areas such as pharmaceutical pricing pressures and supply chain vulnerabilities. Overall, these factors make AbbVie a strong and stable investment with potential for growth in the coming years.
Bears say
AbbVie is facing increasing competition in the immunology space, potential negative pipeline results, and legal risks from patent challenges. Despite its strong portfolio and potential for growth, the company's valuation is currently trading at a premium compared to its peers and may face pressures on its operating margins, resulting in a slower EPS growth and contraction in its P/E multiple. The addition of the Apogee pipeline and diversity initiatives show long-term sustainability efforts, but there are still looming risks and uncertainties in the company's future.
This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.
AbbVie (ABBV) Analyst Forecast & Price Prediction
Start investing in AbbVie (ABBV)
Order type
Buy in
Order amount
Est. shares
0 shares